Breadcrumb

[A12-07] Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2012-01-31 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 297 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A18-44] Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-12] Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A13-44] Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed

[A11-16] Ipilimumab - Consultation on content and completeness of the dossier
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2012-05-02 Extract of dossier assessment 297 kBPDFdownload file
2012-05-02 Dossier assessment (German version) 480 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) [PDF, 297 kB]

Federal Joint Committee (G-BA)

2012-08-02 A G-BA decision was published.

G-BA documents on this decision (German only)

Press releases

2012-05-02 Considerable added benefit of ipilimumab in advanced melanoma



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close